Which Thunderbirds are Go?

Whenever we see a novel emerging niche with a raft of early stage agents coming to the fore, I always remember the salutary lesson we learned from the rise and fall of the BET/Bromodomain landscape.

This particular development attracted a lot of companies – big and small – with various permutations (selective, dual, pan inhibitors) entering clinical pipelines.  It wasn’t to be though, for it all collapsed once it was realised they were toxic and numerous projects were suddenly abandoned left, right, and centre.

Of course, not all targeted agents go poof by the wayside in the same fashion – as the PD(L)1 checkpoint and CD19 CAR-T cell therapies will certainly attest!

In our latest landscape review we take a look at an emerging target with a dozen agents in competition, the majority of which are either in the clinic already or undergoing IND enabling studies.

The good news is they are not all based on the same modality, which only adds to the interestingness of the niche.

While it’s unlikely all of the current agents will successfully make it past the post, I have a strong intuition at least one of them will.  The question is, which one?

To learn more about these early stage oncology compounds, check out the links below…

To continue reading our latest highlights on oncology new product development including commentary and analysis BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers

Posted by